Lingping Zhu, Haiyan Zhang, Lili Wang, Xuefeng Yang
{"title":"1990年至2021年自闭症负担的全球和区域趋势:来自全球疾病负担研究的数据重新分析和预测","authors":"Lingping Zhu, Haiyan Zhang, Lili Wang, Xuefeng Yang","doi":"10.2147/RMHP.S510506","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aims to investigate global incidence rates and disability-adjusted life-years (DALYs) for autism spectrum disorder (ASD) from 1990 to 2021 and forecast trends for the next 25 years.</p><p><strong>Methods: </strong>Utilizing data from the Global Burden of Disease (GBD) study, we examined global and country-specific ASD incidence, prevalence, and burden. We also calculated age-standardized prevalence, analyzed by sex, age groups, sociodemographic index (SDI) regions, and GBD regions, and made predictions for the future.</p><p><strong>Results: </strong>In 2021, the GBD reported global age-standardized ASD incidence and prevalence at 0.019% and 0.788%, respectively. High-income Asia-Pacific had the highest burden, while Tropical Latin America had the lowest. From 1990 to 2021, global age-standardized prevalence rose by 1.95%, and incidence by 5.20%. Females and low-middle SDI regions saw the most significant increases in incidence, while the Caribbean and Serbia saw decreases. High-income Asia Pacific and Japan experienced the largest prevalence increases, and Middle SDI, East Asia, high-income Asia Pacific, and Equatorial Guinea saw the most significant DALY increases, with Oceania showing the largest decrease. Predictive models forecast continued increases in incidence, prevalence, and DALYs from 2022 to 2046.</p><p><strong>Conclusion: </strong>ASD incidence, prevalence, and DALYs are rising annually, with notable increases in females and middle-low income countries and a decline in the Caribbean. Tailored screening and interventions based on regional rates are essential for improving the health of individuals with autism.</p>","PeriodicalId":56009,"journal":{"name":"Risk Management and Healthcare Policy","volume":"18 ","pages":"2151-2168"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222627/pdf/","citationCount":"0","resultStr":"{\"title\":\"Global and Regional Trends in Autism Burden from 1990 to 2021: A Data Re-Analysis and Prediction from the Global Burden of Disease Study.\",\"authors\":\"Lingping Zhu, Haiyan Zhang, Lili Wang, Xuefeng Yang\",\"doi\":\"10.2147/RMHP.S510506\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study aims to investigate global incidence rates and disability-adjusted life-years (DALYs) for autism spectrum disorder (ASD) from 1990 to 2021 and forecast trends for the next 25 years.</p><p><strong>Methods: </strong>Utilizing data from the Global Burden of Disease (GBD) study, we examined global and country-specific ASD incidence, prevalence, and burden. We also calculated age-standardized prevalence, analyzed by sex, age groups, sociodemographic index (SDI) regions, and GBD regions, and made predictions for the future.</p><p><strong>Results: </strong>In 2021, the GBD reported global age-standardized ASD incidence and prevalence at 0.019% and 0.788%, respectively. High-income Asia-Pacific had the highest burden, while Tropical Latin America had the lowest. From 1990 to 2021, global age-standardized prevalence rose by 1.95%, and incidence by 5.20%. Females and low-middle SDI regions saw the most significant increases in incidence, while the Caribbean and Serbia saw decreases. High-income Asia Pacific and Japan experienced the largest prevalence increases, and Middle SDI, East Asia, high-income Asia Pacific, and Equatorial Guinea saw the most significant DALY increases, with Oceania showing the largest decrease. Predictive models forecast continued increases in incidence, prevalence, and DALYs from 2022 to 2046.</p><p><strong>Conclusion: </strong>ASD incidence, prevalence, and DALYs are rising annually, with notable increases in females and middle-low income countries and a decline in the Caribbean. Tailored screening and interventions based on regional rates are essential for improving the health of individuals with autism.</p>\",\"PeriodicalId\":56009,\"journal\":{\"name\":\"Risk Management and Healthcare Policy\",\"volume\":\"18 \",\"pages\":\"2151-2168\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222627/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Risk Management and Healthcare Policy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/RMHP.S510506\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Risk Management and Healthcare Policy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/RMHP.S510506","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
Global and Regional Trends in Autism Burden from 1990 to 2021: A Data Re-Analysis and Prediction from the Global Burden of Disease Study.
Objective: This study aims to investigate global incidence rates and disability-adjusted life-years (DALYs) for autism spectrum disorder (ASD) from 1990 to 2021 and forecast trends for the next 25 years.
Methods: Utilizing data from the Global Burden of Disease (GBD) study, we examined global and country-specific ASD incidence, prevalence, and burden. We also calculated age-standardized prevalence, analyzed by sex, age groups, sociodemographic index (SDI) regions, and GBD regions, and made predictions for the future.
Results: In 2021, the GBD reported global age-standardized ASD incidence and prevalence at 0.019% and 0.788%, respectively. High-income Asia-Pacific had the highest burden, while Tropical Latin America had the lowest. From 1990 to 2021, global age-standardized prevalence rose by 1.95%, and incidence by 5.20%. Females and low-middle SDI regions saw the most significant increases in incidence, while the Caribbean and Serbia saw decreases. High-income Asia Pacific and Japan experienced the largest prevalence increases, and Middle SDI, East Asia, high-income Asia Pacific, and Equatorial Guinea saw the most significant DALY increases, with Oceania showing the largest decrease. Predictive models forecast continued increases in incidence, prevalence, and DALYs from 2022 to 2046.
Conclusion: ASD incidence, prevalence, and DALYs are rising annually, with notable increases in females and middle-low income countries and a decline in the Caribbean. Tailored screening and interventions based on regional rates are essential for improving the health of individuals with autism.
期刊介绍:
Risk Management and Healthcare Policy is an international, peer-reviewed, open access journal focusing on all aspects of public health, policy and preventative measures to promote good health and improve morbidity and mortality in the population. Specific topics covered in the journal include:
Public and community health
Policy and law
Preventative and predictive healthcare
Risk and hazard management
Epidemiology, detection and screening
Lifestyle and diet modification
Vaccination and disease transmission/modification programs
Health and safety and occupational health
Healthcare services provision
Health literacy and education
Advertising and promotion of health issues
Health economic evaluations and resource management
Risk Management and Healthcare Policy focuses on human interventional and observational research. The journal welcomes submitted papers covering original research, clinical and epidemiological studies, reviews and evaluations, guidelines, expert opinion and commentary, and extended reports. Case reports will only be considered if they make a valuable and original contribution to the literature. The journal does not accept study protocols, animal-based or cell line-based studies.